Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
Comi, Giancarlo
2000.
Why treat early multiple sclerosis patients?.
Current Opinion in Neurology,
Vol. 13,
Issue. 3,
p.
235.
Arnold, Anthony C.
and
Lee, Andrew G.
2001.
Systemic Disease and Neuro-ophthalmology: Annual Update 2000 (Part I).
Journal of Neuro-ophthalmology,
Vol. 21,
Issue. 1,
p.
46.
Rieckmann, P.
2001.
Multiple Sklerose.
p.
109.
MacLean, Heather J.
and
Freedman, Mark S.
2001.
Immunologic therapy for relapsing-remitting multiple sclerosis.
Current Neurology and Neuroscience Reports,
Vol. 1,
Issue. 3,
p.
277.
Zettl, U. K.
Dressler, D.
and
Guthoff, R.
2001.
Multiple Sklerose.
p.
135.
Goodin, Douglas S.
2001.
Interferon-?? Therapy in Multiple Sclerosis.
Drugs,
Vol. 61,
Issue. 12,
p.
1693.
Calabresi, Peter A.
2002.
Considerations in the treatment of relapsing-remitting multiple sclerosis.
Neurology,
Vol. 58,
Issue. 8_suppl_4,
Coyle, P K
and
Hartung, H-P
2002.
Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response.
Multiple Sclerosis Journal,
Vol. 8,
Issue. 1,
p.
2.
Chofflon, Michel
and
Ben-Amor, Ali-Frederic
2002.
Long-term benefits of early and high doses of interferon β-1a treatment in relapsing–remitting multiple sclerosis.
Clinical Neurology and Neurosurgery,
Vol. 104,
Issue. 3,
p.
244.
Freedman, M S
Blumhardt, L D
Brochet, B
Comi, G
Noseworthy, J H
Sandberg-Wollheim, M
and
Sørensen, P Soelberg
2002.
International consensus statement on the use of disease-modifying agents in multiple sclerosis.
Multiple Sclerosis Journal,
Vol. 8,
Issue. 1,
p.
19.
Jeffery, Douglas
Bashir, Khurram
Buchwald, Linda
Coyle, Patricia
Freedman, Mark
Markowitz, Clyde
Rammohan, Kottil
Reder, Tony
Sharief, Mo
and
Wolinsky, Jerry
2002.
Optimizing immunomodulatory therapy for MS patients: an integrated management model.
Journal of the Neurological Sciences,
Vol. 201,
Issue. 1-2,
p.
89.
Coyle, PK
and
Hartung, H-P.
2002.
Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response.
Multiple Sclerosis Journal,
Vol. 8,
Issue. 1_suppl,
p.
2.
Johnson, K P
Brooks, B R
Ford, C C
Goodman, A D
Lisak, R P
Myers, L W
Pruitt, A A
Rizzo, M A
Rose, J W
Weiner, L P
and
Wolinsky, J S
2003.
Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial.
Multiple Sclerosis Journal,
Vol. 9,
Issue. 6,
p.
585.
Flachenecker, Peter
and
Rieckmann, Peter
2003.
Early Intervention in Multiple Sclerosis.
Drugs,
Vol. 63,
Issue. 15,
p.
1525.
2004.
Treatment optimization in multiple sclerosis: report of an international consensus meeting.
European Journal of Neurology,
Vol. 11,
Issue. 1,
p.
43.
Comi, G.
and
Moiola, L.
2004.
Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis.
p.
1.
Rieckmann, P.
and
Toyka, K. V.
2004.
Escalating immunotherapy of multiple sclerosis.
Journal of Neurology,
Vol. 251,
Issue. 11,
p.
1329.
Freedman, Mark S.
Patry, David G.
Grand'Maison, François
Myles, Mary Lou
Paty, Donald W.
and
Selchen, Daniel H.
2004.
Treatment Optimization in Multiple Sclerosis.
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques,
Vol. 31,
Issue. 2,
p.
157.
Johnson, K. P.
Ford, C. C.
Lisak, R. P.
and
Wolinsky, J. S.
2005.
Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data.
Acta Neurologica Scandinavica,
Vol. 111,
Issue. 1,
p.
42.
Flachenecker, Peter
2005.
Intramuscular Interferon-??-1a: In Patients at High Risk of Developing Clinically Definite Multiple Sclerosis.
CNS Drugs,
Vol. 19,
Issue. 1,
p.
63.